Comparative Pharmacology
Head-to-head clinical analysis: JANUVIA versus TRADJENTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JANUVIA versus TRADJENTA.
JANUVIA vs TRADJENTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of dipeptidyl peptidase-4 (DPP-4), increasing levels of active incretin hormones (GLP-1, GIP), enhancing glucose-dependent insulin secretion and suppressing glucagon release.
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It slows the inactivation of incretin hormones GLP-1 and GIP, increasing their levels, which stimulates insulin secretion and suppresses glucagon release in a glucose-dependent manner.
100 mg orally once daily
5 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life: 12.4 hours. Clinical context: supports once-daily dosing in patients with normal renal function.
Terminal elimination half-life is approximately 12.5 hours at steady state, consistent with once-daily dosing and supporting 24-hour DPP-4 inhibition.
Renal: approximately 87% (79% unchanged sitagliptin, 16% metabolites). Fecal/biliary: 13% (metabolites and unchanged drug).
Approximately 85% of the dose is excreted in feces (mostly as unchanged parent drug) and about 5% in urine (largely as metabolites). Biliary excretion accounts for the majority of fecal elimination.
Category C
Category C
DPP-4 Inhibitor
DPP-4 Inhibitor